Search

Displaying results 6401 - 6410 of 10000 in total
  1. Indication

    Uremia

    go.drugbank.com/conditions/DBCOND0020343
    Drugs: Amino acids · Potassium citrate
    Synonyms: Uremia NOS, Uremia, NOS
  2. Drug

    Nandrolone decanoate

    go.drugbank.com/drugs/DB08804
    ApprovedIllicitInvestigational

    Nandrolone decanoate, also known as nandrolone caprinate, is an alkylated anabolic steroid indicated in the management of anemia of renal insufficiency and as an adjunct therapy in the treatment of senile and postmenopausal osteoporosis....

  3. Indication

    T-Cell/Histiocyte-Rich Large B-Cell Lymphoma

    go.drugbank.com/conditions/DBCOND0082251
    Drugs: Polatuzumab vedotin
    Synonyms: Diffuse large B-cell lymphoma NOS, Malignant lymphoma, histiocytic, NOS
  4. Indication

    Laryngitis

    go.drugbank.com/conditions/DBCOND0014068
    Drugs: Amylmetacresol · Benzocaine · Benzydamine · Guaifenesin · Oxolamine · Silver proteinate +3 more
    Synonyms: Laryngitis NOS, Laryngitis, NOS
  5. Indication

    Recurrent Pericarditis

    go.drugbank.com/conditions/DBCOND0020320
    Drugs: Rilonacept
    Synonyms: Pericarditis NOS, Pericarditis, NOS
  6. Indication

    Hemolytic Anemia

    go.drugbank.com/conditions/DBCOND0028410
    Drugs: Bupivacaine · Voxelotor
    Synonyms: Hemolytic anemia (NOS), Anemia hemolytic (NOS)
  7. Indication

    Eczematous rash

    go.drugbank.com/conditions/DBCOND0099487
    Drugs: Betamethasone · Difluocortolone · Fusidic acid
    Synonyms: Eczema NOS, Eczema, NOS
  8. Drug

    Nigericin

    go.drugbank.com/drugs/DB14056
    Experimental

    It is produced by Streptomyces hygroscopicus. (From Merck Index, 11th ed)

  9. Drug

    Autologous Hematopoietic Peripheral Blood Stem Cells

    go.drugbank.com/drugs/DB17067
    Investigational

    Autologous hematopoietic peripheral blood stem cells were tested in a clinical trial (NCT00424489) by Northwestern University for the treatment of refractory myasthenia gravis.

  10. Drug

    REC-994

    go.drugbank.com/drugs/DB15616
    Investigational

    REC-994 was cleared by the FDA in July, 2018 for a phase I trial for the treatment of cerebral cavernous malformation (CCM).